百济神州终止TIGIT抗体欧司珀利单抗肺癌治疗临床开发计划 已累计投入超20亿元

每日经济新闻
04 Apr

每经记者 林姿辰 每经编辑 文多4月3日,百济神州(SH688235)宣布停止TIGIT(一种免疫检查点蛋白)抗体Ociperlimab(欧司珀利单抗,BGB-A1217)作为肺癌潜在治疗方法的临床开发计划。根据预先计划的无效性分析结果,独立数据监查委员会(IDMC)建议终止3期临床试验(AdvanTIG-302)。试验总体有效性和安全性数据评估表明,该研究或难以达到总生存期主要终点。据披露...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10